fausto petrelli

Dr. fausto petrelli

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in JAMA Network Open
Verified
Journal Article
Closed access
PDF file
FPfausto petrelli
fausto petrelli
ACAlessio Cortellini
Alessio Cortellini
AIAlice Indini
Alice Indini
GTGianluca Tomasello
Gianluca Tomasello
Michele GhidiniMichele Ghidini
Michele Ghidini
AZAlberto Zaniboni
Alberto Zaniboni
Obesity, defined as a body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) greater than 30, is a chronic disease with increasing prevalence around the world, largely contributing to important health issues in most countries.1 Alongside body fat, which is a general risk factor for serious illness (eg, metabolic syndrome), greater cardiometabolic risk has also been associated with the localization of excess fat in the visceral adipose tissue and ectopic deposits.2 Several large epidemiologic studies have evaluated the association between obesity and mortality. In particular, a meta-analysis of 230 cohort studies including more than 30 million individuals3 found that both obesity and overweight were associated with an increased risk of all-cause mortality. Despite the evidence that excess mortality increases with increasing BMI, some studies have reached the conclusion that elevated BMI may improve survival in patients with cardiovascular disease, a phenomenon called the obesity paradox.4

1 March 2015 in European Journal of Cancer
Verified
Journal Article
Closed access
FPFilippo Pietrantonio
Filippo Pietrantonio
FPfausto petrelli
fausto petrelli
ACAndrea Coinu
Andrea Coinu
MBMaria Di Bartolomeo
Maria Di Bartolomeo
KBKaren Borgonovo
Karen Borgonovo
SBSandro Barni
Sandro Barni

1 March 2020 in Annals of Surgery
Verified
Journal Article
Closed access
FPfausto petrelli
fausto petrelli
FTFrancesca Trevisan
Francesca Trevisan
MCMary Cabiddu
Mary Cabiddu
GSGiovanni Sgroi
Giovanni Sgroi
LBLorenza Bruschieri
Lorenza Bruschieri
LTLuca Turati
Luca Turati
Background: The addition of induction chemotherapy to concomitant neoadjuvant chemoradiation in locally advanced rectal cancer could increase pathological downstaging and act on occult micrometastatic disease, leading ultimately to a better outcome. A systematic review was carried out of the existing literature on the treatment outcomes of total neoadjuvant therapy (TNT) on locally advanced rectal cancer. TNT was defined as chemotherapy using cycles of induction and/or consolidation in conjunction with standard chemoradiotherapy prior to surgery.Methods: A systematic search of PubMed, Embase, and the Cochrane Library was performed according to the PRISMA statement up until January 2019. The primary endpoints were complete pathologic response (pCR), disease-free survival, and overall survival rates.Results: A total of 28 studies (3 retrospective and 25 prospective for a total of 3579 patients) were included in the final analysis (n = 2688 treated with TNT and n = 891 with neoadjuvant chemoradiotherapy therapy). The pooled pCR rate was 22.4% (95% CI 19.4%–25.7%) in all patients treated with TNT (n = 27 studies with data available). In n = 10 comparative studies with data available, TNT was found to increase the odds of pCR by 39% (1.40, 95% CI 1.08–1.81,P= 0.01).Conclusions: The addition of induction or consolidation chemotherapy to standard neoadjuvant chemoradiotherapy results in a higher pCR rate. Given that the comparative analysis was derived from few randomized publications, large confirmatory trials should be carried out before a strong recommendation is made in favor of TNT.

1 February 2014 in European Urology
Verified
Journal Article
Closed access
FPfausto petrelli
fausto petrelli
ACAndrea Coinu
Andrea Coinu
MCMary Cabiddu
Mary Cabiddu
MGMara Ghilardi
Mara Ghilardi
IVIvano Vavassori
Ivano Vavassori
SBSandro Barni
Sandro Barni

27 February 2020 in Cancers
Verified
Journal Article
Open access
PDF file
FPfausto petrelli
fausto petrelli
DSDiego Signorelli
Diego Signorelli
Michele GhidiniMichele Ghidini
Michele Ghidini
AGAntonio Ghidini
Antonio Ghidini
EPElio Gregory Pizzutilo
Elio Gregory Pizzutilo
Gianluca TomaselloGianluca Tomasello
Gianluca Tomasello
Immune checkpoint inhibitors (ICIs) can elicit toxicities by inhibiting negative regulators of adaptive immunity. Sometimes, management of toxicities may require systemic glucocorticoids. We performed a systematic review and meta-analysis of published studies to evaluate the correlation between steroids use, overall survival (OS), and progression-free survival (PFS) in cancer patients treated with ICIs. Publications that compared steroids with non-steroid users in cancer patients treated with ICIs from inception to June 2019 were identified by searching the EMBASE, PubMed, SCOPUS, Web of Science, and Cochrane Library databases. The pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using a random-effects model. Patients (studies, n = 16; patients, n = 4045) taking steroids were at increased risk of death and progression compared to those not taking steroids (HR = 1.54, 95% CI: 1.24–1.91; p = 0.01 and HR = 1.34, 95% CI: 1.02–1.76; p = 0.03, respectively). The main negative effect on OS was associated with patients taking steroids for supportive care (HR = 2.5, 95% CI 1.41–4.43; p < 0.01) or brain metastases (HR = 1.51, 95% CI 1.22–1.87; p < 0.01). In contrast, steroids used to mitigate adverse events did not negatively affect OS. In conclusion, caution is needed when steroids are used for symptom control. In these patients, a negative impact of steroid use was observed for both OS and PFS.

4 September 2015 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
FPfausto petrelli
fausto petrelli
GVG. Viale
G. Viale
MCM. Cabiddu
M. Cabiddu
SBS. Barni
S. Barni